{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:23:05Z","timestamp":1740176585427,"version":"3.37.3"},"reference-count":37,"publisher":"Federacion Colombiana de Obstetricia y Ginecologia","issue":"1","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Colomb. Obstet. Ginecol."],"abstract":"<jats:p>Objetivo: definir la incidencia de deseo sexual hipoactivo (DSH) en mujeres que planifican con el implante subd\u00e9rmico de levonorgestrel (LNG) despu\u00e9s de 12 meses, y conocer otros efectos adversos. Materiales y m\u00e9todos: estudio de cohorte, cuyas participantes fueron mujeres mayores de 18 a\u00f1os sin hijos ni embarazos previos y con pareja estable, a quienes se les hab\u00eda insertado el implante de LNG al menos tres meses previos en una cl\u00ednica privada de car\u00e1cter universitario en Armenia (Quind\u00edo), Colombia, entre 2014 y 2019. Se excluyeron mujeres con antecedentes de disfunci\u00f3n sexual, infecciones de transmisi\u00f3n sexual en los \u00faltimos 6 meses, peso mayor a 89 Kg y dificultades para el seguimiento. El muestreo fue consecutivo. Se describieron las caracter\u00edsticas de la poblaci\u00f3n estudiada, se estim\u00f3 la incidencia acumulada de DSH y efectos adversos relacionados con el implante subd\u00e9rmico de LNG a 12 meses de seguimiento. Se aplic\u00f3 como instrumento el \u00cdndice de Funci\u00f3n Sexual Femenino. Se utiliz\u00f3 estad\u00edstica descriptiva. Resultados: participaron 238 mujeres cuya edad media fue de 24,69 (DE \u00b1 5,82) a\u00f1os. Se determin\u00f3 una incidencia de deseo sexual hipoactivo del 18,82%. El 60,25% de las mujeres fueron diagnosticadas con DHS en los primeros 6 meses de seguimiento. Los efectos adversos se hicieron presentes desde los primeros 3 meses de la inserci\u00f3n del implante, el sangrado irregular (62,34%) fue el m\u00e1s frecuente, seguido de la amenorrea (38,91%) y el aumento de peso (33,89%). Conclusiones: es importante que los m\u00e9dicos y las usuarias se informen sobre la presencia del trastorno de deseo sexual hipoactivo y los efectos adversos que pueden surgir con el uso del implante subd\u00e9rmico de levonorgestrel. Las futuras investigaciones deben confirmar estos hallazgos, as\u00ed como su eventual base fisiol\u00f3gica.<\/jats:p>","DOI":"10.18597\/rcog.3520","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T19:38:01Z","timestamp":1616528281000},"page":"33-42","source":"Crossref","is-referenced-by-count":1,"title":["Incidencia a un a\u00f1o de deseo sexual hipoactivo en mujeres que planifican con implante subd\u00e9rmico de levonorgestrel. Estudio de cohorte. Armenia, Colombia, 2014-2019"],"prefix":"10.18597","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-9680","authenticated-orcid":false,"given":"Franklin Jos\u00e9","family":"Espitia De La Hoz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7913","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"86896","doi-asserted-by":"crossref","unstructured":"Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, et al. Hypoactive Sexual Desire Disorder: International Society for the Study of Women\u2019s Sexual Health (ISSWSH) Expert Consensus Panel Review. Mayo Clin Proc. 2017; 92(1):114-28. https:\/\/doi.org\/10.1016\/j.mayocp.2016.09.018","DOI":"10.1016\/j.mayocp.2016.09.018"},{"key":"86897","doi-asserted-by":"crossref","unstructured":"Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual Problems and Distress in United States Women: Prevalence and Correlates. Obstet Gynecol. 2008; 112(5):970-8. https:\/\/doi.org\/10.1097\/AOG.0b013e3181898cdb","DOI":"10.1097\/AOG.0b013e3181898cdb"},{"key":"86898","doi-asserted-by":"crossref","unstructured":"Espitia-De La Hoz FJ. Prevalence and characterisation of sexual dysfunctions in women, in 12 Colombian cities, 2009-2016. Rev Colomb Obstet Ginec. 2018; 69(1):9-21. https:\/\/doi.org\/10.18597\/rcog.3035","DOI":"10.18597\/rcog.3035"},{"key":"86899","doi-asserted-by":"crossref","unstructured":"Hayes RD, Dennerstein L, Bennett CM, Koochaki PE, Leiblum SR, Graziottin A. Relationship between hypoactive sexual desire disorder and aging. Fertil Steril. 2007; 87(1):107-12. https:\/\/doi.org\/10.1016\/j.fertnstert.2006.05.071","DOI":"10.1016\/j.fertnstert.2006.05.071"},{"key":"86900","doi-asserted-by":"crossref","unstructured":"West SL, D\u2019Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med. 2008; 168(13):1441-9 https:\/\/doi.org\/10.1001\/archinte.168.13.1441","DOI":"10.1001\/archinte.168.13.1441"},{"key":"86901","doi-asserted-by":"crossref","unstructured":"Abdo CH, Valadares AL, Oliveira WM Jr, Scanavino MT, Afif-Abdo J. Hypoactive sexual desire disorder in a population-based study of Brazilian women: associated factors classified according to their importance. Menopause. 2010; 17(6):1114-21. https:\/\/doi.org\/10.1097\/gme.0b013e3181e19755","DOI":"10.1097\/gme.0b013e3181e19755"},{"key":"86902","doi-asserted-by":"crossref","unstructured":"Clayton AH, Goldfischer ER, Goldstein I, Derogatis L, Lewis-D\u2019Agostino DJ, Pyke R. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med. 2009; 6(3):730-8. https:\/\/doi.org\/10.1111\/j.1743-6109.2008.01153.x","DOI":"10.1111\/j.1743-6109.2008.01153.x"},{"key":"86903","doi-asserted-by":"crossref","unstructured":"Sills T, Wunderlich G, Pyke R, Segraves RT, Leiblum S, Clayton A, et al. The Sexual Interest and Desire Inventory\u2014Female (SIDI-F): item response analyses of data from women diagnosed with hypoactive sexual desire disorder. J Sex Med 2005; 2:801\u201318. https:\/\/doi.org\/10.1111\/j.1743-6109.2005.00146.x","DOI":"10.1111\/j.1743-6109.2005.00146.x"},{"key":"86904","doi-asserted-by":"crossref","unstructured":"Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26(2):191-208. https:\/\/doi.org\/10.1080\/009262300278597","DOI":"10.1080\/009262300278597"},{"key":"86905","doi-asserted-by":"crossref","unstructured":"Rosen RC. Assessment of female sexual dysfunction: review of validated methods. Fertil Steril. 2002; 77 Suppl 4:S89-93. https:\/\/doi.org\/10.1016\/s0015-0282(02)02966-7","DOI":"10.1016\/S0015-0282(02)02966-7"},{"key":"86906","doi-asserted-by":"crossref","unstructured":"Vallejo-Medina P, P\u00e9rez-Dur\u00e1n C, Saavedra-Roa A. Translation, Adaptation, and Preliminary Validation of the Female Sexual Function Index into Spanish (Colombia). Arch Sex Behav. 2018; 47(3):797-810. https:\/\/doi.org\/10.1007\/s10508-017-0976-7","DOI":"10.1007\/s10508-017-0976-7"},{"key":"86907","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Herrezuelo I, Hita-Contreras F, Mart\u00ednez-Amat A, Aibar-Almaz\u00e1n A, Cruz-D\u00edaz D, Wangensteen R, et al. The female sexual function index: reliability and validity in Spanish postmenopausal women. Menopause. 2019; 26(4):401-8. https:\/\/doi.org\/10.1097\/GME.0000000000001305","DOI":"10.1097\/GME.0000000000001305"},{"key":"86908","doi-asserted-by":"crossref","unstructured":"Casado-Espada NM, de Alarc\u00f3n R, de la Iglesia-Larrad JI, Bote-Bonaechea B, Montejo \u00c1L. Hormonal Contraceptives, Female Sexual Dysfunction, and Managing Strategies: A Review. J Clin Med. 2019; 8(6):908. https:\/\/doi.org\/10.3390\/jcm8060908","DOI":"10.3390\/jcm8060908"},{"key":"86909","unstructured":"Espitia-De La Hoz FJ. Educaci\u00f3n y asesoramiento sexual para hombres y mujeres. Bogot\u00e1. Editorial Nomos S.A. Primera edici\u00f3n. 2018; 8(1):99-100."},{"key":"86910","doi-asserted-by":"crossref","unstructured":"Espitia-De La Hoz FJ, Orozco-Gallego H. Alteration of the sexual response cycle in women using combined oral contraceptives. Salud Uninorte. Barranquilla (Col.) 2018; 34 (2):430-42. https:\/\/doi.org\/10.14482\/sun.34.2.613.94","DOI":"10.14482\/sun.34.2.613.94"},{"key":"86911","doi-asserted-by":"crossref","unstructured":"Bjelica A, Kapamadzija A, Maticki-Sekulic M. Hormones and female sexuality. Med. Pregl. 2003; 56(9-10):446-50. https:\/\/doi.org\/10.2298\/MPNS0310446B","DOI":"10.2298\/MPNS0310446B"},{"key":"86912","doi-asserted-by":"crossref","unstructured":"Sanders SA, Graham CA, Bass JL, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception. 2001; 64(1):51\u20138. https:\/\/doi.org\/10.1016\/s0010-7824(01)00218-9","DOI":"10.1016\/S0010-7824(01)00218-9"},{"key":"86913","doi-asserted-by":"crossref","unstructured":"Black A, Guilbert E, Costescu D, Dunn S, Fisher W, Kives S, et al. No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception. J. Obstet. Gynaecol. Canada 2017; 39(4):229\u201368.e5. https:\/\/doi.org\/10.1016\/j.jogc.2016.10.005","DOI":"10.1016\/j.jogc.2016.10.005"},{"key":"86914","doi-asserted-by":"crossref","unstructured":"Smith NK, Jozkowski KN, Sanders SA. Hormonal contraception and female pain, orgasm and sexual pleasure. J. Sex. Med. 2014; 11(2):462\u201370. https:\/\/doi.org\/10.1111\/jsm.12409","DOI":"10.1111\/jsm.12409"},{"key":"86915","doi-asserted-by":"crossref","unstructured":"Casey PM, MacLaughlin KL, Faubion SS. Impact of Contraception on Female Sexual Function. J. Women\u2019s Heal. 2017; 26(3):207-13. https:\/\/doi.org\/10.1089\/jwh.2015.5703","DOI":"10.1089\/jwh.2015.5703"},{"key":"86916","doi-asserted-by":"crossref","unstructured":"Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review. Eur J Contracept Reprod Health Care. 2013; 18(1):27-43. https:\/\/doi.org\/10.3109\/13625187.2012.728643","DOI":"10.3109\/13625187.2012.728643"},{"key":"86917","doi-asserted-by":"crossref","unstructured":"Boozalis A, Tutlam NT, Chrisman Robbins C, Peipert JF. Sexual Desire and Hormonal Contraception. Obstet Gynecol. 2016; 127(3):563-72. https:\/\/doi.org\/10.1097\/AOG.0000000000001286","DOI":"10.1097\/AOG.0000000000001286"},{"key":"86918","doi-asserted-by":"crossref","unstructured":"Wan LS, Stiber A, Lam LY. The levonorgestrel two-rod implant for long-acting contraception: 10 years of clinical experience. Obstet Gynecol. 2003; 102(1):24- 6. https:\/\/doi.org\/10.1016\/s0029-7844(03)00482-4","DOI":"10.1016\/S0029-7844(03)00482-4"},{"key":"86919","doi-asserted-by":"crossref","unstructured":"Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol. 2017; 130(5):e251-e269. https:\/\/doi.org\/10.1097\/AOG.0000000000002400","DOI":"10.1097\/AOG.0000000000002400"},{"key":"86920","doi-asserted-by":"crossref","unstructured":"Sivin I, Wan L, Ranta S, Alvarez F, Brache V, Mishell DR Jr, et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. Contraception. 2001; 64(1):43-9. https:\/\/doi.org\/10.1016\/s0010-7824(01)00226-8","DOI":"10.1016\/S0010-7824(01)00226-8"},{"key":"86921","doi-asserted-by":"crossref","unstructured":"Critchley HO, Bailey DA, Au CL, Affandi B, Rogers PA. Immunohistochemical sex steroid receptor distribution in endometrium from long-term subdermal levonorgestrel users and during the normal menstrual cycle. Hum Reprod. 1993; 8(10):1632-9. https:\/\/doi.org\/10.1093\/oxfordjournals.humrep.a137904","DOI":"10.1093\/oxfordjournals.humrep.a137904"},{"key":"86922","doi-asserted-by":"crossref","unstructured":"Curtis KM. Safety of implantable contraceptives for women: data from observational studies. Contraception. 2002; 65(1):85-96. https:\/\/doi.org\/10.1016\/s0010-7824(01)00291-8","DOI":"10.1016\/S0010-7824(01)00291-8"},{"key":"86923","doi-asserted-by":"crossref","unstructured":"Sivin I. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. Drug Saf. 2003; 26(5):303-35. https:\/\/doi.org\/10.2165\/00002018-200326050-00002","DOI":"10.2165\/00002018-200326050-00002"},{"key":"86924","doi-asserted-by":"crossref","unstructured":"Aisien AO. Contraception with levonorgestrel subdermal implants (Norplant) in Benin-City, Nigeria: a 12-year review. Afr J Reprod Health. 2007; 11(1):90-7. https:\/\/doi.org\/10.2307\/30032491","DOI":"10.2307\/30032491"},{"key":"86925","doi-asserted-by":"crossref","unstructured":"Brache V, Faundes A, Alvarez F, Cochon L. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception. 2002; 65(1):63-74. https:\/\/doi.org\/10.1016\/s0010-7824(01)00289-x","DOI":"10.1016\/S0010-7824(01)00289-X"},{"key":"86926","doi-asserted-by":"crossref","unstructured":"Hickey M, d\u2019Arcangues C. Vaginal bleeding disturbances and implantable contraceptives. Contraception. 2002; 65(1):75-84. https:\/\/doi.org\/10.1016\/s0010-7824(01)00292-x","DOI":"10.1016\/S0010-7824(01)00292-X"},{"key":"86927","doi-asserted-by":"crossref","unstructured":"Fraser IS, Tiitinen A, Affandi B, Brache V, Croxatto HB, Diaz S, et al. Norplant consensus statement and background review. Contraception. 1998; 57(1):1-9. https:\/\/doi.org\/10.1016\/s0010-7824(97)00200-x","DOI":"10.1016\/S0010-7824(97)00200-X"},{"key":"86928","doi-asserted-by":"crossref","unstructured":"Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception. 1998; 58(6 Suppl):99S-107S. https:\/\/doi.org\/10.1016\/s0010-7824(98)00123-1","DOI":"10.1016\/S0010-7824(98)00123-1"},{"key":"86929","doi-asserted-by":"crossref","unstructured":"Sivin I. Contraception with NORPLANT\u00ae implants, Human Reproduction. Contraception 1994; 9(10): 1818\u201326. https:\/\/doi.org\/10.1093\/oxfordjournals.humrep.a138341","DOI":"10.1093\/oxfordjournals.humrep.a138341"},{"key":"86930","doi-asserted-by":"crossref","unstructured":"Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception. 1995; 52(4):215-9. https:\/\/doi.org\/10.1016\/0010-7824(95)00189-h","DOI":"10.1016\/0010-7824(95)00189-H"},{"key":"86931","doi-asserted-by":"crossref","unstructured":"Cullins VE, Blumenthal PD, Remsburg RE, Huggins GR. Preliminary experience with Norplant in an innercity population. Contraception. 1993; 47(2):193-203. https:\/\/doi.org\/10.1016\/0010-7824(93)90091-k","DOI":"10.1016\/0010-7824(93)90091-K"},{"key":"86932","doi-asserted-by":"crossref","unstructured":"Sivin I, Alvarez F, Mishell DR Jr, Darney P, Wan L, Brache V, et al. Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic. Contraception. 1998; 58(5):275-82. https:\/\/doi.org\/10.1016\/s0010-7824(98)00112-7","DOI":"10.1016\/S0010-7824(98)00112-7"}],"container-title":["Revista Colombiana de Obstetricia y Ginecolog\u00eda"],"original-title":[],"link":[{"URL":"https:\/\/revista.fecolsog.org\/index.php\/rcog\/article\/download\/3520\/3686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revista.fecolsog.org\/index.php\/rcog\/article\/download\/3520\/3686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T13:13:21Z","timestamp":1618578801000},"score":1,"resource":{"primary":{"URL":"https:\/\/revista.fecolsog.org\/index.php\/rcog\/article\/view\/3520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3,30]]}},"URL":"https:\/\/doi.org\/10.18597\/rcog.3520","relation":{},"ISSN":["2463-0225","0034-7434"],"issn-type":[{"type":"electronic","value":"2463-0225"},{"type":"print","value":"0034-7434"}],"subject":[],"published":{"date-parts":[[2021,3,30]]}}}